65 results about "Antibody therapy" patented technology

The disclosure provides methods of identifying a subject for treatment with an anti-ox-LDL antibody. The disclosure also provides methods of treating a subject with an anti-ox-LDL antibody, wherein the subject has been identified to as a candidate for anti-oxLDL antibody therapy. The methods described herein use computed tomography to identify subjects who are a candidate for anti-oxLDL antibody therapy, wherein a subject may be determined to be a candidate for anti-oxLDL antibody therapy by evaluating their fat attenuation index (FAI), perivascular adipose tissue (PVAT), pericoronary adipose tissue, FAI score, FAI percentile, or CaRi-Heart® Risk score.

The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.

The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.

The present invention addresses the problem of providing: a novel biomarker useful for the prediction of prognosis of a cancer patient or for the detection of cancer; a means capable of specifically recognizing the biomarker; and a novel cancer therapeutic agent.　Provided is a biomarker for cancer, the biomarker comprising claudin 16 (CLDN16) protein or a peptide fragment thereof, or a transcript of CLDN16 gene or a nucleic acid fragment thereof. Also provided is an anti-CLDN16 antibody or a fragment thereof, which comprises: a heavy-chain variable region that includes CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, and CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3; and a light-chain variable region that includes CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6.

The present application relates to the technical field of biotechnology, in particular to a programmed death receptor ligand 2 monoclonal antibody and application thereof. The present application provides a PD-L2 monoclonal antibody, amino acid sequences of three CDR regions of a heavy chain thereof; amino acid sequences of three CDR regions of a light chain thereof; or amino acid sequences obtained by substitution, deletion or addition of one or more amino acids of the amino acid sequences, or amino acid sequences functionally identical or similar to the amino acid sequences; or amino acid sequences having at least 80% homology with the sequences. The present application widens the possibility of antibody therapy for blocking PD1 / PD1 ligand, and compared with existing PD-L2 monoclonal antibodies, the 8E3 antibody has unique amino acid sequences and CDR region sequences, high affinity and high specificity. The 8E3 antibody can be used in ELISA, Western blot and flow cytometry detection, and has wide application.

The invention discloses a biomarker for monitoring the curative effect of a PD-1 antibody of a PD-L1Positive gastric cancer patient, and relates to the technical field of biomedical detection, and the biomarker is laminin gamma 2. According to the invention, the laminin gamma2 is used as a novel biomarker for monitoring the curative effect of the PD-1 treatment antibody of the PD-L1Positive gastric cancer patient, experiments prove that the serum level of the laminin gamma2 is higher than that of healthy people in the gastric cancer patient and is in positive correlation with a prognosis related factor sPD-L1, the tissue expression of the PD-L1Positive patient is higher, and the serum level of a person without PD-1 antibody treatment response is higher; it is proved that the marker has good progress monitoring value, treatment reaction differences can be effectively distinguished, and the blank of lack of PD-1 antibody curative effect monitoring markers for patients of the type is filled up.

Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be preferably delivered by gene therapy methods, particularly as a recombinant adeno-associated virus (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are "biobetters" as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody.

Provided for are compositions and methods for treating amyloid related imaging abnormalities (ARIA) with selective Janus kinase (JAK) inhibitors in Alzheimer's disease (AD) patients or patients with other with neurodegenerative disease or cerebral amyloid angiopathy-related inflammation (CAAri) undergoing anti-amyloid therapy, including anti- amyloid antibody therapies. Particularly useful are JAK inhibitors selective against JAK1 and tyrosine kinase 2 (TYK2).

Provided herein is an ActRII antibody dosing regimen for the treatment of metabolic disorders, including obesity. In some embodiments, the dosing regimen is preceded by administration of a loading dose of the ActRII antibody, which can further optimize the efficacy of treatment.

This invention discloses a bispecific nanobody targeting CXCL1 and PD-L1 and its applications, belonging to the fields of antibody engineering and bioengineering technology. The bispecific nanobody targeting CXCL1 and PD-L1 comprises at least one nanobody recognizing CXCL1 and one nanobody recognizing PD-L1, with the nanobody monomers linked by a linker. The bispecific nanobody targeting PD-L1 / CXCL1 provided by this invention has a unique structure, enabling it to specifically recognize and bind to both CXCL1 and PD-L1. It achieves an affinity of 1.08 nM for CXCL1 and 1.09 nM for PD-L1, effectively preventing immune escape-induced resistance to antibody therapy, making it suitable for a wider range of patients, and providing a new approach for CRC treatment.

To provide tumor-associated antigens suitable for targeted antibody therapy against cancer.SOLUTION: Antigen binding molecules that specifically bind ALPPL2 and ALPP, but not ALPL and ALPI are provided. Also provided are chimeric molecules and pharmaceutical compositions comprising the antigen-binding molecules, methods of reducing the expression or activity of ALPPL2 in cancer cells, and methods of treating cancers in a subject.SELECTED DRAWING: None

Targeting immunosuppressive B cell populations using bispecific or multivalent targeting molecules presents a potential pathway for therapeutic interventions that effectively modulate antitumor immune responses and improve therapeutic outcomes. Therefore, we provide engineered antibody-based therapeutics that can effectively and selectively target immunosuppressive B cell populations for the treatment of cancer. [Solution] A multispecific antibody is provided comprising a CD19 antigen-binding component configured to bind to CD19 and a CD38 antigen-binding component configured to bind to CD38, wherein the CD19 antigen-binding component comprises an antibody or an antigen-binding fragment thereof, and the CD38 antigen-binding component comprises an antibody or an antigen-binding fragment thereof.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

An immune related adverse event marker and a kit. The immune related adverse event marker comprises CD183. The immune related adverse event marker can effectively predict immune related adverse events caused by programmed death receptor 1 antibody / programmed death-ligand antibody therapy, thereby facilitating intervention and treatment of immune related adverse events.

The present disclosure provides a method of mitigating amyloid-related imaging abnormalities in a subject receiving an antibody therapy, such as a monoclonal antibody, for the treatment of Alzheimer's disease by administering an effective amount of an Angiotensin-(1 -7) receptor agonist to the subject.

The present disclosure provides compositions comprising a designed ankyrin repeat protein (DARPin) for use in treating Shiga toxin (Stx)-producing Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). The high thermostability and high microbial expression yield make DARPin an attractive alternative to antibody therapeutics. The present disclosure provides monomer proteins, dimer proteins, and trimer proteins, as well as pharmaceutical compositions and methods utilizing the same.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The present invention relates to a composition and method capable of effectively predicting the therapeutic responsiveness of a subject to an antibody therapeutic agent for asthma, using blood EDN levels or urine EDN levels. In particular, the present invention can significantly increase the efficiency of predicting therapeutic responsiveness by configuring, as appropriate parameters, blood and urine EDN levels together with the number of blood eosinophils that were conventionally used to predict therapeutic responsiveness to antibody therapeutic agents for asthma. Therefore, the present invention can be usefully utilized for predicting the therapeutic responsiveness of a subject to various antibody therapeutic agents for asthma, such as mepolyizumab, resluzumab, and dupilumab.

We provide antibody-based therapeutics against CD155 that can treat CNS cancers and systemic cancers. [Solution] Humanized antibodies or antigen-binding fragments specific to the poliovirus receptor (PVR) are used to prepare antibody-drug conjugates (ADCs) that target nucleic acids, peptides, proteins, drugs, and radiopharmaceuticals to cancer cells. These antibodies can be used for checkpoint blockade, blocking PVR (CD155) from binding to TIGIT. Humanized antibodies are used either alone or in combination with other checkpoint inhibitors known in the art. Humanized antibodies modulate the PVR-DNAM-1 axis to upregulate DNAM1 (CD226) expression on T cells or NK cells, thereby restoring the immune surveillance mechanism. The antibodies are incorporated into CAR-T cells or CAR NK cells.

The invention discloses targeted nano-particles TPPO NPs capable of efficiently delivering and locally controlling oxygen release to improve the curative effect of sonodynamic and antibody therapy, and relates to a preparation method of multifunctional nano-particles and application of the multifunctional nano-particles in tumor diagnosis and treatment. According to the preparation method disclosed by the invention, targeting nanoparticles capable of efficiently carrying O2 are prepared by using a lipidated sound-sensitive agent, namely pyropheophorbide a lipid, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-NHS, perfluorobromooctane (PFOB) and trastuzumab (Tra). Under the targeting effect of trastuzumab, the nanoparticles recognize HER-2 positive gastric cancer cells, and efficient enrichment of the nanoparticles at the HER-2 positive gastric cancer cells is achieved together with permeation enhancing and retention enhancing effects. Under the ultrasonic action, on one hand, the sonosensitizer generates reactive oxygen species (ROS), and the sonodynamic therapy effect is achieved; on the other hand, O2 carried by perfluorobromooctane PFOB in the nanoparticles can be controllably released, so that the hypoxia of tumors is relieved, and the sonodynamic and antibody treatment effects are enhanced.

To address a need to develop a test to measure the eligibility of patients for antibody therapy by providing markers which are associated with favorable and unfavorable outcomes, respectively, in antibody therapy; and to demonstrate that these markers are useful as markers for prognosing clinical outcome for cancer patients, thereby allowing the findings presented herein to be used to select a suitable treatment for a cancer patient and, in particular, to decide whether antibody therapy should be administered to a cancer patient.SOLUTION: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.SELECTED DRAWING: None

Provided herein are treatment methods and uses, including administering a composition containing recombinant chimeric antigen receptor (CAR)-engineered NK cells (g-NK cells) lacking FcRγ chain expression in combination with a monoclonal antibody. Among the provided methods and uses are those for treating cancers such as multiple myeloma or lymphoma.

The present invention provides pharmaceutically acceptable salts of compounds of Formula I that are potent EP4 receptor antagonists and can be used for treating cancer or inflammatory diseases alone or in combination with antibody therapy, radiation therapy, anti-metabolite chemotherapy to a subject in need thereof.

The invention relates to a B cell immune reset method of a non-integrated in-vivo panCAR based on circRNA, and belongs to the technical field of immunotherapy. The invention provides a B cell resetting preparation. The main component of the B cell resetting preparation is spot type circRNA (Ribonucleic Acid) for coding an anti-CD19 chimeric antigen receptor (Anti-CD19-CAR); firstly, RNA molecules capable of coding Anti-CD19-CAR are subjected to cyclization treatment, then the RNA molecules are loaded on an LNP carrier to form a compound, and the compound can be used for B cell / antibody removal. After the preparation is injected into a body, panCAR cells (including CAR-T, CAR-NK and CAR-Macrophage) can be generated, compared with an antibody therapy and a CAR-T cell therapy, more thorough and safer B cell resetting can be achieved, and the preparation has application potential in the aspects of treating autoimmune diseases and allergic asthma and delaying senescence.

The invention concerns branched oncolytic peptides and uses thereof in the treatment of cancer diseases. Pharmaceutical compositions comprising them are also described. The peptides of the invention were found to be active in the treatment of particular tumors called "cold tumors", which cannot benefit from the most advanced antibody therapies.

The invention relates to the field of breast cancer treatment, in particular to a PDIA3 protein targeting monoclonal antibody and application of the PDIA3 protein targeting monoclonal antibody in breast cancer treatment. According to the present invention, the IgG antibody in tumors, lymph nodes and serum is detected by using the IP-MS technology, the breast cancer tumor antigen disulfide isomerase A3 (PDIA3) is screened by analyzing the characteristics of the IgG antibody, and it is proved that the PDIA3 antigen can induce the breast cancer mouse model to produce the local humoral immune response. Meanwhile, it is found that a PDIA3 specific monoclonal antibody based on memory B cell reconstruction in TLN shows potent immune effect activity, wherein an Ab88 antibody can mediate an ADCC / ADCP effect and inhibit tumor growth. In conclusion, the invention provides the local targeting antigen PDIA3 protein with antibody therapy transformation potential and the specific antibody Ab88 thereof, and a new choice is provided for accurate treatment of breast cancer.

Provided herein are methods of treatment and uses involving the administration of a composition comprising an NK cell (g-NK cell) that lacks expression of the FcR gamma chain, engineered with a recombinant chimeric antigen receptor (CAR), in combination with a monoclonal antibody. The provided methods and uses include methods and uses for treating cancer, such as multiple myeloma or lymphoma.

The invention provides an immune-related adverse reaction marker and a kit. The immune-related adverse reaction marker and the kit can effectively predict immune-related adverse reaction caused by programmed death receptor 1 antibody / programmed death ligand antibody treatment. The immune-related adverse reaction marker comprises CCL20, CXCL11, CXCL10 or CXCL9, and the immune-related adverse reaction marker comprises CCL20, CXCL11, CXCL10 or CXCL9. The immune-related adverse reaction marker and the kit provided by the technical scheme of the invention can effectively predict immune-related adverse reactions, so that the immune-related adverse reactions can be conveniently intervened and treated.

Using protein structural probes one can identify tumor-induced or -produced (TIPS) factors that bind to therapeutic antibodies and change their dynamic structure, thereby negatively affecting their humoral immune functions as well as their pharmacologic activity. Using such protein structural probes and TIPS factors one can screen and identify inhibitors that can counter the binding of TIPS factors to affected therapeutic antibodies. These inhibitors can be used in the presence of a TIPS factor-susceptible antibody (TSA) for treating cancer. An inhibitor can be used alone or in combination with chemotherapy for treating cancer. Patients can be screened to identify those with low or no TIPS factor production as candidates for antibody therapy even in the case in which the antibody is a TSA. Conversely, those with high TIPS factor production are candidates for inhibitor therapy.

Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.